Description medications: Acyclovir (Aciclovir)
ACYCLOVIR (Aciclovir). 9- (2-Hydroxy) etoksimetilguanin, or 2-amino-1, 9-dihydro-9- (2-hydroxy) ethoxymethyl-6H-purin-6-one.
Synonyms: Viroleks, Zovirax, Asusloguanosine, Acyclovir, Cycloviran, Milavir, Virolex .
Protivovirucny drug, especially effective against viruses of herpes simplex and herpes zoster (zoster).
Acyclovir is an analogue of purine nucleoside dezoksiguanidina, normal DNA component.
The similarity of structures and acyclovir acyclovir dezoksiguanidina allows to interact with the viral enzymes, which leads to an interruption of viral replication. After introduction of acyclovir into an affected cell herpes thymidine kinase under the influence of released virus, acyclovir is converted into acyclovir monophosphate which enzymes of the host cell transformed in acyclovir diphosphate and then to the active acyclovir triphosphate form, which blocks the implementation of the viral DNA. The drug acts selectively on viral DNA synthesis. DNA replication hoeyaina cells (human cells) acyclovir triphosphate almost no effect.
Acyclovir herpes prevents new elements disease, reduces the likelihood of cutaneous dissemination and visceral complications accelerates education crusts, reduces pain in the acute phase of herpes zoster.
The drug also has immunostimulatory effects.
Acyclovir used intravenously, orally and topically (as a cream or ointment).
When administered acyclovir absorbed only partially (about 20%). The half-life when administered intravenously and administered about 3 hours. Provided mainly kidneys unchanged, partly in the form of a metabolite (9-karboksimetoksimetilguanin). In renal insufficiency significantly increase the half-life (up to 19, 5 hours).
Intravenous acyclovir in infections caused by the herpes simplex virus in patients with compromised immune systems; in severe forms of primary infections of the genital organs in case of infection caused by the herpes simplex virus; infections caused by the herpes zoster virus; for the prevention of infections caused by the herpes simplex virus in patients with severely impaired immune system (with organ transplants, cancer chemotherapy).
Intravenously administered to adults and children over 12 years: 5 mg / kg 3 times a day (every 8 hours); in patients with herpes zoster immune system disorders - 10 mg / kg every 8 hours; Children from 3 months to 12 years - 5 mg / kg (250 mg / m 2 body surface area).
In violation of renal excretory function and elderly persons, reduce the dose (based on creatinine clearance).
For intravenous administration, the contents of 1 vial with acyclovir (250 mg) is diluted in 10 ml of isotonic sodium chloride solution or a special solvent. The solution can be administered by injection slowly (within an hour) or applied dropwise to the resulting solution (25 mg in 1 ml) was diluted further in 50 ml of a solvent [or the contents of two vials (500 mg) of acyclovir is diluted in 100 ml of solvent].